Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

2 reasons why I’ve got my eyes on the Sonic Healthcare (ASX:SHL) share price

There are two very good reasons why I've got my eyes on the Sonic Healthcare Ltd (ASX:SHL) share price. More COVID testing is on the cards.

There are two very good reasons why I’ve got my eyes on the Sonic Healthcare Ltd (ASX: SHL) share price.

Sonic Healthcare is one of the largest pathology businesses in Australia. It also has large market positions in both Europe and the US.

These two reasons are why I’ve got my eyes on the Sonic Healthcare share price:

COVID-19 testing continues

Sonic has conducted millions of COVID tests across its different operating countries. Some investors seemed to think that the COVID-19 testing boost to earnings, generating an excellent amount of cashflow for the business.

With the latest variant, Omicron, racing around the world there is yet another wave of testing that Sonic Healthcare seems as though it’s going to be involved in.

I do hope that the world can move on from COVID-19 sooner rather than later, but that doesn’t seem to be the case yet. More cases and more testing should mean more dollars for Sonic Healthcare.

Higher earnings should be supportive for the Sonic Healthcare share price.

Acquisitions

With all of that profit that Sonic is making, it’s not giving shareholders a bonanza of dividends (though the payments are growing). Instead, it’s using that profit to make useful bolt-on acquisitions to improve the business and lock in earnings growth.

Sonic Healthcare has announced the acquisition of ProPath. The ASX share described the business as a high quality, medically led anatomical pathology company based in Dallas, Texas.

ProPath’s annual revenue is around US$110 million. With its 50 pathologists, it serves over 1,000 physicians and more than 20 hospital groups across 45 states.

Sonic said that the acquisition is a very significant step in the ongoing development of Sonic’s anatomical pathology operations in the US and is part of the long-term strategy of integrating different parts of pathology as a seamless service in the US, with revenue and cost synergies, with better service for referrers and patients.

The US anatomical pathology market is estimated to be more than US$10 billion per annum in the country.

Summary thoughts on the Sonic Healthcare share price

Sonic shares have risen 29% over the last year. I think it’s a compelling blue chip business with reliable core earnings, a defensive dividend stream and the potential for more acquisitions.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content